Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy
The present study examines the clinical significance of serum neuron-specific enolase (NSE) in patients with non-germinal center B-cell type (non-GCB) of diffuse large B-cell lymphoma (DLBCL) that received rituximab chemotherapy. Serum NSE values were measured using electrochemiluminescence assay in 53 patients. About 54.7% of the DLBCL patients had positive expression of serum NSE (>15.20 ng/ml), which closely correlated with performance status, serum LDH level, B symptoms, IPI scores, and Ann-Arbor stages (P < 0.05). The mean serum NSE value in patients with non-GCB subtype of DLBCL was significantly higher than that of GCB subtype of DLBCL (P = 0.001), and among patients in non-GCB subtype group, there was significant difference in the 5-year OS rate between NSE-positive group and negative group (28.3% vs. 81.6%, P < 0.001). Furthermore, serum NSE level was found to be an independent prognostic factor in patients with non-GCB subtype. Serum NSE may be a novel marker of disease aggressiveness as well as a prognostic factor for non-GCB subtype of DLBCL in the era of rituximab.
基金：
National Natural Science Foundation of China [30471976]; Science and technology projects of Guangdong Province [2010B031600233, 2010A090200019]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2011]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
通讯作者：
通讯机构：[1]Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China[*1]Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Wang Liang,Liu Panpan,Chen Xiaoqin,et al.Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy[J].MEDICAL ONCOLOGY.2012,29(3):2153-2158.doi:10.1007/s12032-011-0049-z.
APA：
Wang, Liang,Liu, Panpan,Chen, Xiaoqin,Geng, Qirong&Lu, Yue.(2012).Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy.MEDICAL ONCOLOGY,29,(3)
MLA：
Wang, Liang,et al."Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy".MEDICAL ONCOLOGY 29..3(2012):2153-2158
